Key result
Prophylactic levosimendan in patients with LVEF ≤30% did not improve hemodynamics or 30-day mortality (7% vs 7%) compared to controls, but reduced MAP and increased norepinephrine requirements.
Why the study?
Does prophylactic levosimendan improve postoperative haemodynamics in patients with LVEF <=30% undergoing cardiac surgery?
Case-Control (n=60)
Does prophylactic levosimendan improve postoperative haemodynamics in patients with LVEF <=30% undergoing cardiac surgery?
Absolute Event Rate: 7% vs 7%
Prophylactic levosimendan before weaning from cardiopulmonary bypass in patients with low LVEF does not improve hemodynamics and may increase the need for postoperative vasopressors.
No takes yet. Share an insight, caveat, or question.
Does not support prophylactic levosimendan in low-LVEF cardiac surgery; leaves open efficacy in randomized trials.
Kolseth et al. (2009) conducted a case-control in Reduced left ventricular function undergoing cardiopulmonary bypass (n=60). Levosimendan vs. Matched controls was evaluated on 30-day mortality. Prophylactic levosimendan in patients with LVEF ≤30% did not improve hemodynamics or 30-day mortality (7% vs 7%) compared to controls, but reduced MAP and increased norepinephrine requirements.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: